Results 251 to 260 of about 6,851,925 (312)
Research progress on carcinogenic factors and personalized treatment of oral cancer. [PDF]
Xu K +6 more
europepmc +1 more source
RvD5 effectively alleviates UC by inhibiting STAT1 signaling to reduce CXCL8 expression in colonic epithelial cells via activation of GPR101, which subsequently decreases the infiltration of neutrophils in the colonic mucosal epithelium. Epimedin A1, a natural allosteric inhibitor of 5‐LOX, demonstrates potential as a therapeutic agent for UC by ...
Pengxiang Guo +9 more
wiley +1 more source
Exploring the role of resilience and quality of life in preoperative fear of cancer recurrence among patients with oral and maxillofacial cancer: A cross-sectional study. [PDF]
Yu J +7 more
europepmc +1 more source
The schematic illustration of the MHSCG platform for spatiotemporal responsive GRb1 release to induce androgen deprivation therapy (ADT) and immunogenic cell death (ICD) multimodal therapy in prostate cancer. Abstract Metal‐based immunotherapy represents a promising strategy for enhancing antitumor efficacy; however, its clinical application is limited
Rui Zan +13 more
wiley +1 more source
Self-perceived oral health, general self-efficacy, and their relations to oral health conditions in head and neck cancer patients in Sweden-a prospective observational study. [PDF]
Karlsson C +4 more
europepmc +1 more source
Targeting Lactate and Lactylation in Cancer Metabolism and Immunotherapy
Lactate, once deemed a metabolic waste, emerges as a central regulator of cancer progression. This review elucidates how lactate and its epigenetic derivative, protein lactylation, orchestrate tumor metabolism, immune suppression, and therapeutic resistance.
Jiajing Gong +5 more
wiley +1 more source
The introduction of a safe discharge network for the ongoing oral healthcare of patients who have completed management for head and neck cancers. [PDF]
Patel J, Ali Z.
europepmc +1 more source
A pH/ROS‐dual‐responsive injectable hydrogel, formed by dynamic boronic ester and Schiff base crosslinking, co‐delivers enoblituzumab (B7‐H3 blocker) and Cl‐amidine (NETs suppressor). Via localized intratumoral delivery, it synergistically reprograms the immunosuppressive tumor microenvironment, overcomes T cell infiltration barriers, restores ...
Huan Li +12 more
wiley +1 more source

